Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Effects of mesh-related complications in vaginal surgery on quality of life.

Kowalik CR, Lakeman MME, de Kraker AT, Roovers JPWR.

Int Urogynecol J. 2019 Jul;30(7):1083-1089. doi: 10.1007/s00192-018-3680-9. Epub 2018 Jun 16.

2.

[Complications after vaginal mesh surgery].

de Kraker AT, Kowalik CR, Roovers JP.

Ned Tijdschr Geneeskd. 2015;160:A9693. Review. Dutch.

PMID:
27007927
3.

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.

Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS, Maybaum J.

Mol Cancer Ther. 2009 Jan;8(1):45-54. doi: 10.1158/1535-7163.MCT-08-0662.

4.

Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.

de Kraker AT, Kenemans P, Smolders RG, Kroeks MV, van der Mooren MJ.

Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):139-44. doi: 10.1016/j.ejogrb.2008.10.007. Epub 2008 Dec 17.

PMID:
19095343
5.

Validity of block randomized clinical trials.

Mijatovic V, de Kraker A, van der Vusse M, Krebber AM.

Fertil Steril. 2008 May;89(5):1281; author reply 1281-2. doi: 10.1016/j.fertnstert.2008.02.155. No abstract available.

PMID:
18486673
6.

Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases.

Smaill JB, Lee HH, Palmer BD, Thompson AM, Squire CJ, Baker EN, Booth RJ, Kraker A, Hook K, Denny WA.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):929-33. doi: 10.1016/j.bmcl.2007.12.046. Epub 2008 Jan 11.

PMID:
18191399
7.

Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases.

Smaill JB, Baker EN, Booth RJ, Bridges AJ, Dickson JM, Dobrusin EM, Ivanovic I, Kraker AJ, Lee HH, Lunney EA, Ortwine DF, Palmer BD, Quin J 3rd, Squire CJ, Thompson AM, Denny WA.

Eur J Med Chem. 2008 Jun;43(6):1276-96. Epub 2007 Aug 6.

PMID:
17869387
8.

4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution.

Palmer BD, Thompson AM, Booth RJ, Dobrusin EM, Kraker AJ, Lee HH, Lunney EA, Mitchell LH, Ortwine DF, Smaill JB, Swan LM, Denny WA.

J Med Chem. 2006 Aug 10;49(16):4896-911.

PMID:
16884302
9.

Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1.

Palmer BD, Smaill JB, Rewcastle GW, Dobrusin EM, Kraker A, Moore CW, Steinkampf RW, Denny WA.

Bioorg Med Chem Lett. 2005 Apr 1;15(7):1931-5.

PMID:
15780636
10.

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.

Pauer LR, Olivares J, Cunningham C, Williams A, Grove W, Kraker A, Olson S, Nemunaitis J.

Cancer Invest. 2004;22(6):886-96.

PMID:
15641487
11.
12.

Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma.

Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Merriman RL.

Mol Cancer Ther. 2003 Apr;2(4):401-8.

13.
14.

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.

Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.

Oncogene. 2002 Dec 12;21(57):8804-16.

15.

Src activation regulates anoikis in human colon tumor cell lines.

Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE.

Oncogene. 2002 Nov 7;21(51):7797-807.

16.

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.

Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H.

Oncogene. 2002 Oct 10;21(46):7001-10.

17.

Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors.

Dorsey JF, Cunnick JM, Lanehart R, Huang M, Kraker AJ, Bhalla KN, Jove R, Wu J.

Leukemia. 2002 Sep;16(9):1589-95.

18.

Src family kinases phosphorylate protein kinase C delta on tyrosine residues and modify the neoplastic phenotype of skin keratinocytes.

Joseloff E, Cataisson C, Aamodt H, Ocheni H, Blumberg P, Kraker AJ, Yuspa SH.

J Biol Chem. 2002 Apr 5;277(14):12318-23. Epub 2002 Jan 25.

19.

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, Sun Y.

Cancer Res. 2001 Nov 15;61(22):8211-7.

20.

Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.

Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R.

Oncogene. 2001 May 3;20(20):2499-513.

21.

Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.

Schroeder MC, Hamby JM, Connolly CJ, Grohar PJ, Winters RT, Barvian MR, Moore CW, Boushelle SL, Crean SM, Kraker AJ, Driscoll DL, Vincent PW, Elliott WL, Lu GH, Batley BL, Dahring TK, Major TC, Panek RL, Doherty AM, Showalter HD.

J Med Chem. 2001 Jun 7;44(12):1915-26.

PMID:
11384237
22.

3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.

Thompson AM, Connolly CJ, Hamby JM, Boushelle S, Hartl BG, Amar AM, Kraker AJ, Driscoll DL, Steinkampf RW, Patmore SJ, Vincent PW, Roberts BJ, Elliott WL, Klohs W, Leopold WR, Showalter HD, Denny WA.

J Med Chem. 2000 Nov 2;43(22):4200-11.

PMID:
11063616
23.

Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.

Kraker AJ, Hartl BG, Amar AM, Barvian MR, Showalter HD, Moore CW.

Biochem Pharmacol. 2000 Oct 1;60(7):885-98.

PMID:
10974196
24.

Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60(c-src).

Thompson AM, Rewcastle GW, Boushelle SL, Hartl BG, Kraker AJ, Lu GH, Batley BL, Panek RL, Showalter HD, Denny WA.

J Med Chem. 2000 Aug 10;43(16):3134-47.

PMID:
10956222
25.
26.

Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity.

Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitzki A, Kraker A, Krolewski JJ, Medveczky P, Jove R.

J Biol Chem. 2000 Aug 11;275(32):24935-44.

27.

Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity.

Wang YZ, Wharton W, Garcia R, Kraker A, Jove R, Pledger WJ.

Oncogene. 2000 Apr 20;19(17):2075-85.

28.

Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.

Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N.

Cancer Res. 1999 Dec 15;59(24):6145-52.

29.

Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor.

Palmer BD, Kraker AJ, Hartl BG, Panopoulos AD, Panek RL, Batley BL, Lu GH, Trumpp-Kallmeyer S, Showalter HD, Denny WA.

J Med Chem. 1999 Jul 1;42(13):2373-82.

PMID:
10395478
30.

Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1.

Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD.

J Biol Chem. 1999 Jun 25;274(26):18428-37.

31.

Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth.

Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker AJ, Corey SJ.

Leukemia. 1999 Jun;13(6):855-61.

PMID:
10360372
32.

Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.

Palmer BD, Smaill JB, Boyd M, Boschelli DH, Doherty AM, Hamby JM, Khatana SS, Kramer JB, Kraker AJ, Panek RL, Lu GH, Dahring TK, Winters RT, Showalter HD, Denny WA.

J Med Chem. 1998 Dec 31;41(27):5457-65.

PMID:
9876115
33.

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.

Boschelli DH, Wu Z, Klutchko SR, Showalter HD, Hamby JM, Lu GH, Major TC, Dahring TK, Batley B, Panek RL, Keiser J, Hartl BG, Kraker AJ, Klohs WD, Roberts BJ, Patmore S, Elliott WL, Steinkampf R, Bradford LA, Hallak H, Doherty AM.

J Med Chem. 1998 Oct 22;41(22):4365-77.

PMID:
9784112
34.

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM.

J Med Chem. 1998 Aug 13;41(17):3276-92.

PMID:
9703473
35.

Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway.

Cunnick JM, Dorsey JF, Standley T, Turkson J, Kraker AJ, Fry DW, Jove R, Wu J.

J Biol Chem. 1998 Jun 5;273(23):14468-75.

36.
37.

Inhibitors of tyrosine kinase.

Klohs WD, Fry DW, Kraker AJ.

Curr Opin Oncol. 1997 Nov;9(6):562-8. Review.

PMID:
9370078
38.

Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.

Hamby JM, Connolly CJ, Schroeder MC, Winters RT, Showalter HD, Panek RL, Major TC, Olsewski B, Ryan MJ, Dahring T, Lu GH, Keiser J, Amar A, Shen C, Kraker AJ, Slintak V, Nelson JM, Fry DW, Bradford L, Hallak H, Doherty AM.

J Med Chem. 1997 Jul 18;40(15):2296-303.

PMID:
9240345
39.

Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.

Dahring TK, Lu GH, Hamby JM, Batley BL, Kraker AJ, Panek RL.

J Pharmacol Exp Ther. 1997 Jun;281(3):1446-56.

PMID:
9190882
40.

Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.

Showalter HD, Sercel AD, Leja BM, Wolfangel CD, Ambroso LA, Elliott WL, Fry DW, Kraker AJ, Howard CT, Lu GH, Moore CW, Nelson JM, Roberts BJ, Vincent PW, Denny WA, Thompson AM.

J Med Chem. 1997 Feb 14;40(4):413-26.

PMID:
9046331
41.

Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro.

Denny WA, Rewcastle GW, Bridges AJ, Fry DW, Kraker AJ.

Clin Exp Pharmacol Physiol. 1996 May;23(5):424-7.

PMID:
8713682
42.

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.

Rewcastle GW, Palmer BD, Bridges AJ, Showalter HD, Sun L, Nelson J, McMichael A, Kraker AJ, Fry DW, Denny WA.

J Med Chem. 1996 Feb 16;39(4):918-28.

PMID:
8632415
43.
45.

Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline).

Rummel SA, Kraker AJ, Steinkampf RW, Hook KE, Klohs WD.

Int J Cancer. 1995 Sep 4;62(5):636-42.

PMID:
7665238
46.

Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2'-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases.

Palmer BD, Rewcastle GW, Thompson AM, Boyd M, Showalter HD, Sercel AD, Fry DW, Kraker AJ, Denny WA.

J Med Chem. 1995 Jan 6;38(1):58-67.

PMID:
7837241
47.
48.

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.

Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ.

Science. 1994 Aug 19;265(5175):1093-5.

PMID:
8066447
50.

Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity.

Fry DW, Kraker AJ, Connors RC, Elliott WL, Nelson JM, Showalter HD, Leopold WR.

Anticancer Drug Des. 1994 Aug;9(4):331-51.

PMID:
7916900

Supplemental Content

Loading ...
Support Center